At close: December 20 at 4:00:02 PM EST
Breakdown
TTM
10/31/2023
10/31/2022
10/31/2021
10/31/2020
Total Revenue
--
210.0000
--
512.0000
--
Cost of Revenue
--
161.0000
--
385.0000
--
Gross Profit
--
49.0000
--
127.0000
--
Operating Expense
13,719.0000
11,060.0000
13,875.0000
13,263.0000
9,978.2020
Operating Income
-13,719.0000
-11,011.0000
-13,875.0000
-13,136.0000
-9,978.2020
Net Non Operating Interest Income Expense
1,213.0000
1,081.0000
104.0000
2.0000
33.9230
Other Income Expense
--
--
--
6.0000
-148.0840
Pretax Income
-12,506.0000
-9,930.0000
-13,771.0000
-13,128.0000
-10,092.3630
Net Income Common Stockholders
-12,361.0000
-9,811.0000
-13,595.0000
-12,954.0000
-10,018.3550
Diluted NI Available to Com Stockholders
-12,361.0000
-9,811.0000
-13,595.0000
-12,954.0000
-10,018.3550
Basic EPS
-0.39
-0.32
-0.45
-0.45
-0.45
Diluted EPS
-0.39
-0.32
-0.45
-0.45
-0.45
Basic Average Shares
31,627.2500
30,980.0000
30,374.0000
28,579.0000
22,229.0420
Diluted Average Shares
31,627.2500
30,980.0000
30,374.0000
28,579.0000
22,229.0420
Total Operating Income as Reported
-13,719.0000
-11,011.0000
-13,875.0000
-13,136.0000
-9,978.2020
Total Expenses
13,719.0000
11,221.0000
13,875.0000
13,648.0000
9,978.2020
Net Income from Continuing & Discontinued Operation
-12,361.0000
-9,811.0000
-13,595.0000
-12,954.0000
-10,018.3550
Normalized Income
-12,361.0000
-9,811.0000
-13,595.0000
-12,960.0000
-9,870.2710
Interest Income
1,213.0000
1,081.0000
104.0000
2.0000
33.9230
Net Interest Income
1,213.0000
1,081.0000
104.0000
2.0000
33.9230
EBIT
-13,719.0000
-11,011.0000
-13,875.0000
-13,136.0000
-9,978.2020
EBITDA
-13,679.0000
-10,965.0000
-13,833.0000
-13,076.0000
-9,888.0450
Reconciled Cost of Revenue
--
161.0000
--
385.0000
--
Reconciled Depreciation
40.0000
46.0000
42.0000
60.0000
90.1570
Net Income from Continuing Operation Net Minority Interest
-12,361.0000
-9,811.0000
-13,595.0000
-12,954.0000
-10,018.3550
Total Unusual Items Excluding Goodwill
--
--
--
6.0000
-148.0840
Total Unusual Items
--
--
--
6.0000
-148.0840
Normalized EBITDA
-13,679.0000
-10,965.0000
-13,833.0000
-13,082.0000
-9,739.9610
10/31/2020 - 10/7/1983
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
INMB INmune Bio, Inc.
4.4000
-0.45%
COYA Coya Therapeutics, Inc.
5.24
+1.55%
GANX Gain Therapeutics, Inc.
1.5600
-0.64%
RCKTW Rocket Pharmaceuticals, Inc.
0.0252
-3.82%
LTRN Lantern Pharma Inc.
3.1450
-2.02%
VNDA Vanda Pharmaceuticals Inc.
4.7800
+3.24%
DMAC DiaMedica Therapeutics Inc.
6.41
+31.62%
CEROW CERo Therapeutics Holdings, Inc.
0.0090
-14.29%
FHTX Foghorn Therapeutics Inc.
5.14
+3.21%
BRTX BioRestorative Therapies, Inc.
1.5500
+6.90%